Friday, May 9, 2025
5/9/2025
Deconvoluting CAR T cell heterogeneity to engineer durable antitumor protection - ABSTRACT Chimeric antigen receptor (CAR) T cells are remarkably effective against advanced hematologic tumors, mediating complete remission in >50% of patients. Yet they have limited success against solid tumors due to the immunosuppressive tumor microenvironment (TME). To improve efficacy, CAR T cells can be “armored” with growth factors, such as IL-2 and IL-15, to promote expansion and survival within the TME. Alternatively, “arming” CAR T cells with inflammatory cytokines amplifies antitumor responses by activating host T cells. We recently armored and armed CAR T cells with an IL-2 superkine (Super2) and tissue alarmin IL-33 (hereafter, Super2+33). These cytokines act synergistically and, with multiple CAR constructs, to alter the TME to promote regression of primary and metastatic solid tumors. However, the ability of CAR T cells to provide durable antitumor immunity remains an open question. Analysis of two long-term survivors who received CD19-targeting CAR T cells shows decade-long persistence of CAR T cells, leukemia regression, and loss of normal B cells. Clinical responses are also positively associated with transcriptional features of stem cell memory T (TSCM) cells in the manufactured CAR T-cell product. These data have spurred the field to optimize in-vitro manufacturing conditions to increase memory T-cell potential within the CAR T-cell product. However, the in-vivo fate of individual CAR T cells within a heterogenous CAR T cell population, such as each cell's ability to proliferate, infiltrate tumors, kill, and differentiate into memory T cells, remains unknown. Moreover, it is unclear how CAR engineering and host environmental factors impact the heterogeneity of CAR T cell effector and memory responses. We will test the overall hypothesis that CAR T-cell heterogeneity can be deconvolved to understand how individual T cell subsets behave in vivo and that principles gained through these analyses can help us rationally engineer CAR T-cell populations that balance antitumor effector responses with generation of durably protective antitumor CAR and host circulating (TCIRC) and widely distributed tissue resident (TRM) memory T cells. This hypothesis will be tested in three aims. Aim 1 will use using dynamic lineage recording to deconvolve CAR T cell heterogeneity to reveal individual differentiation trajectories and identify engineering strategies to program CAR stem cell-like (TSCM) and TRM cell fates. Aim 2 will determine the respective requirements for host and CAR T-cell memory. Aim 3 will identify the effect of tumor burden and neoadjuvant immune checkpoint blockade on T-cell precursor subsets and states on CAR T cell differentiation. Successful completion of this study will advance the development of durable adoptive CAR T-cell therapy for melanoma that results in globally distributed memory T cells with optimal fitness and function.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).